NCT00714246 2019-06-24
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Milton S. Hershey Medical Center
Phase 1 Terminated
Clinical Trials
8 trialsNCT00424840 2019-02-01
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
University of Massachusetts, Worcester
Phase 1 Terminated
NCT00200382 2018-08-02
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Montefiore Medical Center
Phase 2 Terminated
NCT00346645 2013-02-06
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT00040768 2013-01-16
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00117351 2011-02-17
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00283634 2011-02-17
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00064636 2005-06-24
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Millennium Pharmaceuticals, Inc.
Phase 1 Terminated